AUM Pharmaceuticals recalled 50,000 cartons of Quick Touch Alcohol Prep Pads on July 21, 2025, due to cGMP deviations. The recall affects sterile pads containing 70% isopropyl alcohol. Consumers should stop using the product immediately and contact the manufacturer.
cGMP Deviations
Consumers and healthcare providers should stop using this product immediately. Contact YANGZHOU YULOU PAPER PRODUCTS CO., LTD or your healthcare provider for guidance. Notification method: Letter
Get instant alerts for Health & Personal Care recalls
Be the first to know. Free instant alerts to your inbox.
The recall involves Quick Touch Alcohol Prep Pads, Lot #: 20240610, and an expiration date of June 2029. The product comes in cartons containing 100 sterile pads each. A total of 500 cases were distributed.
The recall stems from deviations in current Good Manufacturing Practices (cGMP), which could compromise product safety and efficacy. Such deviations can lead to contamination or reduced potency of the alcohol prep pads.
No specific incidents or injuries have been reported related to this recall. However, the potential risks associated with cGMP deviations warrant immediate action.
Consumers should stop using the Quick Touch Alcohol Prep Pads immediately. For further guidance, contact YANGZHOU YULOU PAPER PRODUCTS CO., LTD or consult a healthcare provider.
For assistance, reach out to YANGZHOU YULOU PAPER PRODUCTS CO., LTD. More information is available at the FDA's official recall notice.
Get instant alerts for recalls that affect you. Free forever.
Taro Pharmaceuticals announced a market withdrawal of Diclofenac Sodium, Topical Gel, 3% on January 27, 2026. The withdrawal stems from out of specification viscosity results. Healthcare providers and consumers should stop using the product immediately.
Fresenius Kabi Compounding recalled 1,057 bags of Acyclovir Sodium Injection on February 5, 2026. The recall stems from a lack of assurance of sterility, posing a high health risk. Healthcare providers should cease use immediately and contact the manufacturer for guidance.
Fresenius Kabi Compounding recalled its vancomycin HCl injection on February 5, 2026, due to a lack of assurance of sterility. This Class II recall affects all lots distributed nationwide. Healthcare providers and consumers must stop using the product immediately.
Fresenius Kabi Compounding recalled 1,578 bags of vancomycin HCl injection on February 5, 2026. The company cited a lack of assurance of sterility as the reason for the recall. Healthcare providers and consumers should stop using the product immediately.
Fresenius Kabi Compounding recalled 1,410 bags of ketamine HCl injection on February 5, 2026. The recall stems from a lack of assurance of sterility, posing a high health risk. Healthcare providers and consumers must stop using this product immediately.
Fresenius Kabi Compounding recalled 10,548 bags of thiamine HCl injection on February 5, 2026. The recall follows a lack of assurance of sterility, posing a high health risk. Affected products include several lots expiring between February and May 2026.
Pro Numb Tattoo Numbing Spray was recalled due to cGMP deviations. The recall affects products distributed nationwide in the USA. Consumers should stop using the spray immediately and contact Pro Numb Tattoo Numbing Spray LLC for guidance.
Pro Numb Tattoo Numbing Spray was recalled on February 2, 2026 due to cGMP deviations. The product, containing 4% lidocaine, is distributed by Pro Numb Tattoo Numbing Spray LLC. Consumers should stop using it immediately and contact the company for further guidance.